R&D Insights: How Novartis AG and Pfizer Inc. Allocate Funds

Pharma Giants' R&D: A Decade of Strategic Investment

__timestamp	Novartis AG	Pfizer Inc.
Wednesday, January 1, 2014	9086000000	8393000000
Thursday, January 1, 2015	8935000000	7690000000
Friday, January 1, 2016	9039000000	7872000000
Sunday, January 1, 2017	8972000000	7657000000
Monday, January 1, 2018	9074000000	8006000000
Tuesday, January 1, 2019	9402000000	8650000000
Wednesday, January 1, 2020	8980000000	9405000000
Friday, January 1, 2021	9540000000	13829000000
Saturday, January 1, 2022	9996000000	11428000000
Sunday, January 1, 2023	11371000000	10679000000
Monday, January 1, 2024	10022000000	10930000000

Igniting the spark of knowledge

R&D Spending: A Decade of Innovation

In the ever-evolving pharmaceutical landscape, research and development (R&D) are the lifeblood of innovation. Over the past decade, Novartis AG and Pfizer Inc. have been at the forefront, channeling significant resources into R&D. From 2014 to 2023, Novartis AG consistently increased its R&D spending, peaking in 2023 with a 25% rise from its 2014 levels. Meanwhile, Pfizer Inc. demonstrated a remarkable 60% surge in R&D investment, particularly notable in 2021, when it outpaced Novartis for the first time. This strategic allocation underscores the companies' commitment to pioneering new treatments and maintaining competitive edges. As the pharmaceutical industry faces unprecedented challenges and opportunities, these investments are crucial for driving future breakthroughs and ensuring sustainable growth.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025